SAN DIEGO, April 2 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.
(NYSE: BMR), The Leading Provider of Environmentally Sustainable Real Estate
to the Life Science Industry(R), announced today that the world's leading life
science research center - the Center for Life Science | Boston in the Longwood
Medical Area - has achieved Gold LEED(R) certification for Core and Shell from
the U.S. Green Building Council (USGBC). The property is 91% leased to Beth
Israel Deaconess Medical Center, Children's Hospital Boston, Dana Farber
Cancer Institute, Immune Disease Institute, and Kowa Company, Ltd.
By granting this elite designation, the USGBC recognized the Center for
Life Science | Boston for its design excellence in five key areas of human and
environmental health: sustainable site development, water savings, energy
efficiency, materials selection and indoor environmental quality.
The Center for Life Science | Boston is a 700,000+ square foot research
center that includes laboratory and office space in the heart of Boston's
Longwood Medical Area, surrounded by world class life science research
institutions, hospitals, and biotechnology and pharmaceutical companies,
including Harvard Medical School, Brigham and Women's Hospital, and Merck
Research Laboratories Boston, along with the premier life science tenants of
the Center for Life Science | Boston.
Commenting on the company's latest LEED(R) certification, Alan D. Gold,
BioMed's Chairman and Chief Executive Officer, said, "I congratulate Team
BioMed and all of our development partners at the Center for Life Science |
Boston for this important accomplishment. Our business model is focused on
building a world-class property portfolio in the seven core U.S. life science
markets. Creating a successful, sustainable business extends to the buildings
that we develop. Along with our tenants, we have worked hard to develop
state-of-the-art research facilities that also meet the rigorous requirements
of the USGBC's LEED(R) certification program."
In 1998, the USGBC established the LEED(R) Green Building Rating
System(TM) as a third-party certification program that has become the
nationally accepted benchmark for the design, construction and operation of
high performance green buildings. BioMed has been a successful pioneer in
bringing LEED(R)-certified projects to the life science industry:
BioMed's 500 Kendall Street property in Cambridge, Massachusetts
achieved Platinum LEED(R) certification, the highest rating available.
This property is 100% leased to Genzyme Corporation and was recently
awarded the Boston Society of Architects' Harleston Parker Medal,
which recognizes "the single most beautiful" building or other
structure built in the Metropolitan Boston area in the past ten years.
- The company's 84,000 square foot built-to-suit laboratory and office
facility at its 9865 Towne Centre Drive campus in San Diego was
completed in July, 2008 and received Silver LEED(R) certification.
The property is 100% leased to Illumina, Inc.
- The 650 East Kendall Street building in Cambridge, Massachusetts, a
280,000 square foot joint venture development project between BioMed
and Prudential Real Estate Investors, is scheduled for delivery later
in 2009 and has received LEED(R) Gold pre-certification.
In addition, BioMed is in the process of obtaining LEED(R) certification
for its 675 West Kendall Street building in Cambridge, Massachusetts which is
100% leased to Vertex Pharmaceuticals, and is targeting Gold LEED(R)
Kent Griffin, BioMed's President and Chief Financial Officer, remarked,
"With Gold certification for the Center for Life Science | Boston, we now have
more than 1.2 million square feet of LEED(R)-certified laboratory and office
space in the Cambridge/Boston market. We are seeing increased interest from
prospective tenants in 'green' buildings, along with recent attention from
state and federal government agencies that can provide financial support and
other subsidies for life science organizations that occupy properties which
include green/sustainable design elements."
About BioMed Realty Trust
BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused
on Providing Real Estate to the Life Science Industry(R). The company's
tenants primarily include biotechnology and pharmaceutical companies,
scientific research institutions, government agencies and other entities
involved in the life science industry. BioMed Realty Trust owns or has
interests in 69 properties, representing 112 buildings with approximately 10.4
million rentable square feet, including approximately 1.4 million square feet
of development in progress. The company also owns undeveloped land parcels
adjacent to existing properties that it estimates can support up to 1.4
million rentable square feet. The company's properties are located
predominantly in the major U.S. life science markets of Boston, San Diego, San
Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have
well-established reputations as centers for scientific research. Additional
information is available at www.biomedrealty.com.
The U.S. Green Building Council (USGBC) is a non-profit organization
committed to expanding sustainable building practices. USGBC is composed of
more than 15,000 organizations from across the building industry that are
working to advance structures that are environmentally responsible,
profitable, and healthy places to live and work. Members include building
owners and end-users, real estate developers, facility managers, architects,
designers, engineers, general contractors, subcontractors, product and
building system manufacturers, government agencies, and nonprofits.
The Leadership in Energy and Environmental Design (LEED(R)) Green Building
Rating System(TM) encourages and accelerates global adoption of sustainable
green building and development practices through the creation and
implementation of universally understood and accepted tools and performance
criteria. LEED(R) is a third-party certification program and the nationally
accepted benchmark for the design, construction and operation of high
performance green buildings. LEED(R) gives building owners and operators the
tools they need to have an immediate and measurable impact on their buildings'
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: general risks affecting
the real estate industry (including, without limitation, the inability to
enter into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing, the use of debt to fund acquisitions and developments, and the
ability to refinance indebtedness as it comes due; failure to manage
effectively the company's growth and expansion into new markets, or to
complete or integrate acquisitions and developments successfully; risks and
uncertainties affecting property development and construction; risks
associated with downturns in the national and local economies, increases in
interest rates, and volatility in the securities markets; potential liability
for uninsured losses and environmental contamination; risks associated with
the company's potential failure to qualify as a REIT under the Internal
Revenue Code of 1986, as amended, and possible adverse changes in tax and
environmental laws; and risks associated with the company's dependence on key
personnel whose continued service is not guaranteed. For a further list and
description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE: BioMed Realty Trust, Inc.
Director, Corporate Communications of BioMed Realty
Web Site: http://www.biomedrealty.com